Molecular mechanisms of hormone resistance of breast cancer

A M Scherbakov1, M A Krasil'nikov, N E Kushlinskii

  • 1N. N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia. alex.scherbakov@gmail.com.

Insights

Hormone resistance in breast cancer (BC) is a major challenge. Targeting specific molecular pathways like EGFR, mTOR, and VEGFR offers promising therapeutic strategies for hormone-resistant BC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Over 70% of breast cancer (BC) tumors have steroid hormone receptors, indicating potential for hormone therapy.
  • Hormone resistance is a primary reason for the ineffectiveness of hormone therapy in BC patients.

Purpose of the Study:

  • To analyze the molecular mechanisms underlying hormone resistance in breast cancer.
  • To identify key molecular pathways involved in hormone-resistant BC cell growth and survival.

Main Methods:

  • Analysis of signal pathways of estrogen receptors (ER).
  • Investigation of receptor tyrosine kinases, cell defense proteins (Akt PI3K, mTOR), and cell cycle regulators (Myc, c-Fos, Cyclin D1).
  • Experimental validation of the role of VEGF/VEGFR2, EGF/EGFR, and NF-kappaB in estrogen-independent and hormone-resistant BC growth.

Main Results:

  • High activity of receptor tyrosine kinases, Akt PI3K/mTOR, and cell cycle regulators (Myc, c-Fos, Cyclin D1) are key factors in BC hormone resistance.
  • Estrogen-independent BC growth is driven by VEGF/VEGFR2 and EGF/EGFR signaling pathways.
  • NF-kappaB transcription factor is crucial for hormone-resistant BC cell growth and survival; its suppression enhances sensitivity to antitumor agents.

Conclusions:

  • Molecular pathways including EGFR, HER-2/neu, mTOR, VEGFR, and PI3K/Akt are promising therapeutic targets for BC.
  • Targeting these pathways, including NF-kappaB, could overcome hormone resistance in BC therapy.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

3.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K